Figures computed from official regulatory filings — .
Analysttarget 12.5 USD (+3%) · consensus 1.5/5 · 0 buy · 0 hold · 2 sell
Ownershipinsiders 37.17% · institutions 20.78% · short 2.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for AMARIN CORP PLC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Fountain Healthcare Partners Ltd. | OtherD (derivative) | $3.8M | SEC | ||
| Fountain Healthcare Partners Ltd. |
| Other |
| $3.8M |
| SEC |